6.6324
Schlusskurs vom Vortag:
$6.55
Offen:
$6.52
24-Stunden-Volumen:
197.25K
Relative Volume:
0.56
Marktkapitalisierung:
$444.16M
Einnahmen:
$555.06M
Nettoeinkommen (Verlust:
$-39.48M
KGV:
-11.05
EPS:
-0.6
Netto-Cashflow:
$29.05M
1W Leistung:
-1.64%
1M Leistung:
-5.98%
6M Leistung:
-10.08%
1J Leistung:
-51.40%
Bioventus Inc Stock (BVS) Company Profile
Firmenname
Bioventus Inc
Sektor
Branche
Telefon
(919) 474-6700
Adresse
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Vergleichen Sie BVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
BVS
Bioventus Inc
|
6.64 | 438.14M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
123.72 | 214.96B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.78 | 149.24B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
359.28 | 136.23B | 24.38B | 2.94B | 4.02B | 7.6145 |
|
MDT
Medtronic Plc
|
90.07 | 116.33B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
82.96 | 48.41B | 5.88B | 1.34B | 577.90M | 2.3455 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Hochstufung | Craig Hallum | Hold → Buy |
| 2022-11-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-11-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-11-10 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-01 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioventus Inc Aktie (BVS) Neueste Nachrichten
Is Bioventus Inc. stock attractive for income investors2025 Retail Activity & Free Real-Time Market Sentiment Alerts - newser.com
How strong is Bioventus Inc. stock revenue growth2025 Earnings Impact & Reliable Price Action Trade Plans - newser.com
What To Expect From Bioventus Inc (BVS) Q3 2025 Earnings - Yahoo Finance
Developing predictive dashboards with Bioventus Inc. dataPortfolio Value Report & Accurate Buy Signal Notifications - newser.com
What the charts say about Bioventus Inc. today2025 Earnings Impact & Momentum Based Trading Ideas - newser.com
Can Bioventus Inc. rally from current levelsLayoff News & Free Community Supported Trade Ideas - newser.com
Bioventus Inc. stock prediction for this weekLong Setup & Accurate Entry/Exit Alerts - newser.com
Should you wait for a breakout in Bioventus Inc.Earnings Risk Report & Step-by-Step Trade Execution Guides - newser.com
Will Bioventus Inc. stock deliver long term returnsMarket Growth Report & Reliable Price Breakout Alerts - newser.com
Will Bioventus Inc. stock maintain momentum in 2025July 2025 Intraday Action & AI Forecasted Entry and Exit Points - newser.com
Can Bioventus Inc. stock sustain free cash flow growth2025 Big Picture & Safe Capital Growth Trade Ideas - newser.com
Short interest data insights for Bioventus Inc.July 2025 PostEarnings & Weekly Top Gainers Trade List - newser.com
Why Bioventus Inc. stock is trending among retail tradersBond Market & Capital Efficiency Focused Ideas - newser.com
Detecting price anomalies in Bioventus Inc. with AIInflation Watch & Technical Pattern Alert System - newser.com
Backtesting results for Bioventus Inc. trading strategiesEarnings Recap Summary & Safe Investment Capital Preservation Plans - newser.com
Is Bioventus Inc. stock recession proofQuarterly Profit Report & AI Powered Market Entry Ideas - newser.com
Bioventus Inc. stock chart pattern explained2025 Breakouts & Breakdowns & Intraday High Probability Alerts - newser.com
Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025 - The Manila Times
Bioventus (NASDAQ: BVS) to report Q3 FY2025 before open; 8:30 a.m. ET call - Stock Titan
Finanzdaten der Bioventus Inc-Aktie (BVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):